Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial

被引：17
|
作者：
Katsiki, Niki [1 ]
Athyros, Vasilios G. [1 ]
Mikhailidis, Dimitri P. [2 ]
Mantzoros, Christos [3 ]
机构：
[1] Aristotle Univ Thessaloniki, Hippocrat Hosp, Med Sch, Propedeut Dept Internal Med 2, Thessaloniki, Greece
[2] UCL, Royal Free Hosp Campus, Med Sch, Dept Clin Biochem, London, England
[3] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Internal Med, Div Endocrinol Diabet & Metab, Boston, MA USA
来源：
METABOLISM-CLINICAL AND EXPERIMENTAL | 2017年 / 74卷
关键词：
GENETIC-VARIANTS; REDUCING LIPIDS; STATIN THERAPY; MANAGEMENT; EVOLOCUMAB; EFFICACY; SAFETY; DYSLIPIDEMIA; ASSOCIATION; ALIROCUMAB;
D O I：
10.1016/j.metabol.2017.04.007
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：43 / 46
页数：4
相关论文
共 50 条
  • [1] PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9): A Narrative Review
    Dua, Pamila
    Reeta, K. H.
    JOURNAL OF THE PRACTICE OF CARDIOVASCULAR SCIENCES, 2020, 6 (03) : 226 - 233
  • [2] Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors to treat hypercholesterolemia: Effect on stroke risk
    Milionis, Haralampos
    Barkas, Fotios
    Ntaios, George
    Papavasileiou, Vasileios
    Vemmos, Kostantinos
    Michel, Patrick
    Elisaf, Moses
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2016, 34 : 54 - 57
  • [3] The Use of Monoclonal Antibody-Based Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia
    Parikh, Riya R.
    Breve, Frank
    Magnusson, Peter
    Behzadi, Payam
    Pergolizzi, Joseph
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (06)
  • [4] Hyperlipidemia: Management with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors
    Shahreyar, Muhammed
    Salem, Salem A.
    Nayyar, Mannu
    George, Lekha K.
    Garg, Nadish
    Koshy, Santhosh K. G.
    JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE, 2018, 31 (04) : 628 - 634
  • [5] Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors to Reduce Cardiovascular Inflammation and Outcomes
    Liberale, Luca
    Montecucco, Fabrizio
    Camici, Giovanni G.
    Dallegri, Franco
    Vecchie, Alessandra
    Carbone, Federico
    Bonaventura, Aldo
    CURRENT MEDICINAL CHEMISTRY, 2017, 24 (14) : 1403 - 1416
  • [6] Residual Risk After Treatment of Patients With Atherosclerotic Cardiovascular Disease With Proprotein Convertase Subtilisin-Kexin Type 9 Monoclonal Antibody Therapy (from the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Trial)
    Wong, Nathan D.
    AMERICAN JOURNAL OF CARDIOLOGY, 2017, 120 (07) : 1220 - 1222
  • [7] Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons
    Yadav, K.
    Sharma, M.
    Ferdinand, K. C.
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2016, 26 (10) : 853 - 862
  • [8] Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects
    Wan, Hong
    Gumbiner, Barry
    Joh, Tenshang
    Riel, Tom
    Udata, Chandrasekhar
    Forgues, Philippe
    Garzone, Pamela D.
    CLINICAL THERAPEUTICS, 2017, 39 (11) : 2243 - 2259
  • [9] Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study
    Choi, Joshua
    Khan, Amir M.
    Jarmin, Michael
    Goldenberg, Naila
    Glueck, Charles J.
    Wang, Ping
    LIPIDS IN HEALTH AND DISEASE, 2017, 16
  • [10] Case reports of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition nonresponse
    Saeed, Anum
    Virani, Salim S.
    Jones, Peter H.
    Ballantyne, Christie M.
    Nambi, Vijay
    JOURNAL OF CLINICAL LIPIDOLOGY, 2018, 12 (05) : 1141 - 1145
12345